Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alopecia Totalis Clear all
Not listed Phase 2 Interventional

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

NCT04011748
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Long-Term PF-06651600 for the Treatment of Alopecia Areata

NCT04006457
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Results available

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

NCT04517864
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

NCT02684097
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Plaquenil for Alopecia Areata, Alopecia Totalis

NCT00176982
View directory record Official record
Conditions
Alopecia Areata
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02312882
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Tofacitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Results available

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

NCT03759340
View directory record Official record
Conditions
Alopecia Areata, Alopecia Universalis, Alopecia Totalis
Interventions
ATI 502 0.46% Topical Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
20
States / cities
Rogers, Arkansas • Denver, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Tofacitnib for the Treatment of Alopecia Areata and Variants

NCT02197455
View directory record Official record
Conditions
Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
Interventions
Tofacitinib Administration
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

NCT03551821
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT06747611
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Vancomycin, Neomycin and MTT capsules, Placebo capsules
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

NCT02299297
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tofacitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

NCT03359356
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
56
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Alopecia Areata Registry

NCT00069589
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Autoimmune Hair Loss, Alopecia Partialis
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2099
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

NCT00063076
View directory record Official record
Conditions
Alopecia Areata
Interventions
Targretin Gel 1%
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

NCT03315689
View directory record Official record
Conditions
Alopecia Universalis (AU), Alopecia Totalis (AT)
Interventions
Vehicle, ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

NCT03594227
View directory record Official record
Conditions
Alopecia
Interventions
ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
25
States / cities
Hot Springs, Arkansas • Rogers, Arkansas • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02812342
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Tofacitinib ointment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

NCT02553330
View directory record Official record
Conditions
Alopecia Areata
Interventions
Placebo Cream, Ruxolitinib Phosphate Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 21, 2026, 4:00 PM EDT